&nbsp;

Feb 2025

Drug

degarelix

Other Name(s): Firmagon®

Quick Link(s):

Feb 2025

Drug

decitabine / cedazuridine

Other Name(s): Inqovi®

Quick Link(s):

Feb 2025

Drug

dostarlimab

Other Name(s): Jemperli

Quick Link(s):

Feb 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DGRL

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

degarelix

Drugs Used:

degarelix

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative, Palliative

Funding:

Exceptional Access Program

daSAtinib - PH+ ALL, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DURV

Cancer Type:

Lung,

Small Cell

Intent: Adjuvant

Drugs Used:

durvalumab (Compassionate)

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

DOST(MNT); CRBPPACL+DOST

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Funding:

New Drug Funding Program

Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Drug

durvalumab

Other Name(s): Imfinzi®

Quick Link(s):

May 2025

Regimen

DEXAPOMASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

dexamethasone,

pomalidomide (Unfunded),

selinexor (Unfunded)